GlassScriptPhysician profile
Michael S Lagnese
NPI 1538148465
$4,034.18
in general payments reported to CMS, 2019-2025
30 companies · $38.14 in 2025
The $38.14 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $325 · 2021: $385 · 2022: $1,024 · 2023: $1,289 · 2024: $563 · 2025: $38.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $584.61 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $551.83 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Jazz Pharmaceuticals INC. | $547.71 | 2019-2024 | |
| Insmed, INC. | $272.30 | 2021-2024 | Arikayce |
| Mallinckrodt Hospital Products INC. | $228.26 | 2020-2023 | Acthar |
| Gilead Sciences, INC. | $202.96 | 2023-2025 | Veklury |
| Regeneron Healthcare Solutions, INC. | $184.17 | 2019-2022 | |
| Harmony Biosciences LLC | $177.50 | 2023-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.72 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $152.68 | 2020-2022 | |
| Philips North America LLC | $122.78 | 2022-2024 | (Ak6) Vest Therapy |
| Amgen INC. | $115.08 | 2022-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $82.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.76 | 2020-2024 | Xarelto |
| Mylan Specialty L.P. | $69.65 | 2020-2023 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.83 | 2022-2024 | |
| Resmed Corp | $49.59 | 2019-2020 | |
| Pulmonx Corporation | $44.16 | 2020 | |
| Genentech USA, INC. | $41.60 | 2019-2023 | Xolair |
| Axsome Therapeutics, INC. | $40.42 | 2023 | Sunosi |
| Olympus America INC. | $40.41 | 2020 | |
| Ani Pharmaceuticals, INC. | $35.96 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $31.92 | 2019 | |
| Pfizer INC. | $31.50 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2023 | Aralast |
| Tactile Systems Technology INC | $25.07 | 2024 | Flexitouch Plus, Entre Plus |
| Baxter Healthcare | $24.95 | 2023 | Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $23.83 | 2021 | |
| Abbvie INC. | $18.49 | 2023 | |
| United Therapeutics Corporation | $16.43 | 2024 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lagnese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.